Change of Vertebral Left Atrial Size in Dogs With Preclinical Myxomatous Mitral Valve Disease Prior to the Onset of Congestive Heart Failure.

Abstract

INTRODUCTION/OBJECTIVES: It has been proposed that vertebral left atrial size (VLAS) on thoracic radiographs can be used to assess the left atrial enlargement in dogs with myxomatous mitral valve disease (MMVD). However, it remains unclear whether VLAS can be used to distinguish dogs between pre-clinical MMVD that are at a greater risk of developing congestive heart failure (CHF) from those at a lower risk. We investigated this possibility. ANIMALS, MATERIALS AND METHODS: Forty-one dogs with MMVD were retrospectively classified into one of two groups, a group that developed CHF (group CHF, n&#xa0;=&#xa0;17) or remained CHF-free (group no-CHF, n&#xa0;=&#xa0;24). The value of vertebral heart scale (VHS) and VLAS at three time-points, change in VHS and VLAS at a specific time interval (&#x394;VHS, &#x394;VLAS) and rate of change in the values per month (&#x394;VHS/month, &#x394;VLAS/month) were compared. RESULTS: At the first visit, there were no significant differences in VLAS between the groups. At the median of 105 (interquartile ranges 83-155) days prior to the onset of CHF (group CHF) or the last visit (group no-CHF), VLAS was significantly higher in group CHF (mean, 2.9; standard deviation&#xa0;&#xb1;&#xa0;0.4) than in group no-CHF (2.6&#xa0;&#xb1;&#xa0;0.3) (p&#xa0;=&#xa0;0.028). &#x394;VLAS/month (area under the curve, 0.91; p<0.001) showed high diagnostic accuracy in distinguishing which dogs would develop CHF within 180 days and which would not. CONCLUSIONS: VLAS and &#x394;VLAS/month in dogs with pre-clinical MMVD may be useful to identify dogs at risk of developing CHF within the next 180 days.